HLB unveils roadmap for novel drugs for 3 cancer types by 2026
Korean pharmaceutical company HLB unveiled its roadmap for adding novel anticancer treatments for three cancer types to its portfolio by 2026, as part of its bid to cement its position as an oncology-focused specialist following the anticipated U.S. approval of its targeted anticancer treatment, Rivoceranib, next month.
Feb 7, 2025By Nam Hyun-woo